Autopsy report · NCT00732745

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

“Lost funding for Phase II portion of study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Case Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer

Interventions

docetaxel; oxaliplatin; vandetanib; placebo

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• A Commercial Available Tooth Positioner for the Treatment of Simple Orthodontic Relapse
  “losing of funding for the study” (80% match in meaning)
• Pharmacogenetic Testing for Medication Management.
  “Loss of funding for the continuation of the Study” (80% match in meaning)
• Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
  “Due to lack of funding, phase II of study was not completed.” (77% match in meaning)
• Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
  “Funding for study was withdrawn” (76% match in meaning)
• A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures
  “Study Terminated due to lack of Funding” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.